Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse.
Animals
Antihypertensive Agents
/ pharmacology
Aorta
/ drug effects
Arachidonic Acids
/ pharmacology
Blood Pressure
/ drug effects
Endocannabinoids
/ pharmacology
Enzyme Inhibitors
/ pharmacology
Isoenzymes
/ metabolism
Male
Mice
Mice, Inbred C57BL
Phosphotransferases (Alcohol Group Acceptor)
/ antagonists & inhibitors
Polyunsaturated Alkamides
/ pharmacology
Receptors, Lysosphingolipid
/ metabolism
Vasodilation
/ drug effects
Anandamide
Hypotension
Mouse
Sphingosine kinase
Sphingosine-1-phosphate
Journal
European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354
Informations de publication
Date de publication:
05 Jan 2019
05 Jan 2019
Historique:
received:
07
09
2018
revised:
02
10
2018
accepted:
19
10
2018
pubmed:
26
10
2018
medline:
26
2
2019
entrez:
26
10
2018
Statut:
ppublish
Résumé
In the isolated rat carotid artery, the endocannabinoid anandamide induces endothelium-dependent relaxation via activation of the enzyme sphingosine kinase (SK). This generates sphingosine-1-phosphate (S1P) which can be released from the cell and activates S1P receptors on the endothelium. In anaesthetised mice, anandamide has a well-characterised triphasic effect on blood pressure but the contribution of SK and S1P receptors in mediating changes in blood pressure has never been studied. Therefore, we assessed this in the current study. The peak hypotensive response to 1 and 10 mg/kg anandamide was measured in control C57BL/6 mice and in mice pretreated with selective inhibitors of SK1 (BML-258, also known as SK1-I) or SK2 ((R)-FTY720 methylether (ROMe), a dual SK1/2 inhibitor (SKi) or an S1P
Identifiants
pubmed: 30359564
pii: S0014-2999(18)30612-5
doi: 10.1016/j.ejphar.2018.10.027
pmc: PMC6318480
pii:
doi:
Substances chimiques
Antihypertensive Agents
0
Arachidonic Acids
0
Endocannabinoids
0
Enzyme Inhibitors
0
Isoenzymes
0
Polyunsaturated Alkamides
0
Receptors, Lysosphingolipid
0
Phosphotransferases (Alcohol Group Acceptor)
EC 2.7.1.-
sphingosine kinase
EC 2.7.1.-
anandamide
UR5G69TJKH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-9Subventions
Organisme : British Heart Foundation
ID : FS/08/071/26212
Pays : United Kingdom
Informations de copyright
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.
Références
Gen Pharmacol. 1999 Nov;33(5):415-21
pubmed: 10553883
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14228-33
pubmed: 10588688
Nat Med. 2000 Mar;6(3):313-9
pubmed: 10700234
J Biol Chem. 2000 Jun 30;275(26):19513-20
pubmed: 10751414
Br J Pharmacol. 2000 Aug;130(8):1871-7
pubmed: 10952677
Br J Pharmacol. 2000 Aug;130(8):1878-83
pubmed: 10952678
Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):562-9
pubmed: 11770012
J Histochem Cytochem. 2002 May;50(5):661-70
pubmed: 11967277
J Biol Chem. 2002 Jul 19;277(29):25847-50
pubmed: 12011103
Mol Pharmacol. 2003 Mar;63(3):699-705
pubmed: 12606780
Circulation. 2003 Jul 22;108(3):342-7
pubmed: 12847068
Cancer Res. 2003 Sep 15;63(18):5962-9
pubmed: 14522923
EMBO J. 2003 Oct 15;22(20):5491-500
pubmed: 14532121
J Clin Invest. 2004 Feb;113(4):569-81
pubmed: 14966566
J Physiol. 2004 Jul 15;558(Pt 2):647-57
pubmed: 15121805
Br J Pharmacol. 2004 May;142(1):20-6
pubmed: 15131000
Br J Pharmacol. 2004 Sep;143(2):276-84
pubmed: 15326035
Circulation. 2004 Oct 5;110(14):1996-2002
pubmed: 15451779
J Biol Chem. 2005 Mar 18;280(11):9833-41
pubmed: 15590668
Toxicol Sci. 2005 Jul;86(1):194-9
pubmed: 15829618
FASEB J. 2006 Feb;20(2):340-2
pubmed: 16322129
Cell Metab. 2006 Mar;3(3):167-75
pubmed: 16517404
Mol Pharmacol. 2006 Jul;70(1):41-50
pubmed: 16571654
Am J Physiol Regul Integr Comp Physiol. 2007 Jan;292(1):R440-6
pubmed: 16990495
J Biol Chem. 2007 Sep 14;282(37):27493-502
pubmed: 17635916
Br J Pharmacol. 2007 Nov;152(5):825-31
pubmed: 17704827
Br J Pharmacol. 2007 Dec;152(7):1092-101
pubmed: 17876302
Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H736-49
pubmed: 18024550
J Biol Chem. 2008 May 2;283(18):11954-63
pubmed: 18296752
Blood. 2008 Aug 15;112(4):1382-91
pubmed: 18511810
Pharmacol Rev. 2008 Jun;60(2):181-95
pubmed: 18552276
Annu Rev Biochem. 2009;78:743-68
pubmed: 19231986
Cardiovasc Res. 2009 May 1;82(2):193-200
pubmed: 19282351
Mol Cancer Res. 2009 Jul;7(7):1086-98
pubmed: 19609004
Br J Pharmacol. 2010 Jun;160(3):574-84
pubmed: 20105178
J Clin Invest. 2010 May;120(5):1429-40
pubmed: 20407207
Cell Signal. 2010 Oct;22(10):1536-42
pubmed: 20570726
Br J Pharmacol. 2010 Sep;161(1):176-92
pubmed: 20718749
Trends Mol Med. 2011 Aug;17(8):463-72
pubmed: 21514226
J Clin Invest. 2011 Jun;121(6):2290-300
pubmed: 21555855
Cell Signal. 2011 Oct;23(10):1590-5
pubmed: 21620961
Int Immunopharmacol. 2011 Nov;11(11):1773-9
pubmed: 21798372
Br J Pharmacol. 2012 Apr;165(7):2073-88
pubmed: 22022923
Br J Pharmacol. 2012 May;166(2):510-21
pubmed: 22233379
Br J Pharmacol. 2012 Jun;166(4):1411-8
pubmed: 22251137
Biochim Biophys Acta. 2013 Jan;1831(1):147-56
pubmed: 22801036
PLoS One. 2012;7(8):e42900
pubmed: 22916176
Clin Sci (Lond). 2014 Apr;126(8):545-56
pubmed: 24131465
Br J Pharmacol. 2014 Mar;171(6):1361-78
pubmed: 24329566
Mol Pain. 2014 Nov 28;10:74
pubmed: 25431213
Prog Biophys Mol Biol. 2015 Mar;117(2-3):212-216
pubmed: 25814480
PLoS One. 2015 Sep 14;10(9):e0138142
pubmed: 26367262
Nature. 1993 Sep 2;365(6441):61-5
pubmed: 7689702
Kidney Int. 1994 Oct;46(4):1074-82
pubmed: 7861701
Circ Res. 1994 Dec;75(6):981-9
pubmed: 7955152
Neurol Res. 1994 Aug;16(4):310-2
pubmed: 7984263
J Lipid Res. 1996 Jul;37(7):1601-8
pubmed: 8827530
Hypertension. 1997 May;29(5):1204-10
pubmed: 9149688
J Biol Chem. 1998 May 15;273(20):12576-83
pubmed: 9575218
J Biol Chem. 1998 Sep 11;273(37):23722-8
pubmed: 9726979